CNSide Diagnostics and Plus Therapeutics are proud to collaborate with the Leptomeningeal Cancer Foundation to introduce a new educational resource designed to help patients, caregivers, and healthcare professionals better understand leptomeningeal metastases (LM).

This clinical education poster provides clear, accessible information about LM—an often complex and serious complication of advanced cancer that affects the central nervous system. The goal of this resource is to support awareness, earlier recognition of symptoms, and informed discussions between patients and their care teams.

What Are Leptomeningeal Metastases?

Leptomeningeal Metastases occur when cancer cells spread to the leptomeninges, the delicate membranes surrounding the brain and spinal cord.

LM most commonly arises from cancers such as:

• Breast Cancer
• Lung Cancer
• Melanoma

Once cancer cells enter the cerebrospinal fluid (CSF), they can circulate throughout the central nervous system, making diagnosis and treatment particularly challenging.

However, advances in diagnostics, molecular testing, and targeted therapies are improving how clinicians detect and manage this condition.

Symptoms of Leptomeningeal Metastases

Because LM affects the brain and spinal cord, symptoms can vary widely depending on where cancer cells are present.

Common symptoms may include:

• Persistent headaches
• Nausea or vomiting
• Vision changes or double vision
• Difficulty walking or balance problems
• Weakness in the arms or legs
• Changes in memory or cognitive function

Early recognition of these symptoms can help physicians investigate potential central nervous system involvement sooner.

How Leptomeningeal Metastases Are Diagnosed

Diagnosing LM typically requires a combination of clinical evaluation and specialized testing.

Common diagnostic approaches include:

Neuroimaging

• MRI scans of the brain and spine to identify abnormalities in the meninges.

Cerebrospinal Fluid Testing

• Analysis of CSF obtained through a lumbar puncture to detect cancer cells or tumor-derived biomarkers.

Advanced Molecular Diagnostics

• Emerging technologies that can identify tumor DNA or other molecular signals in the CSF, potentially improving detection sensitivity.

Innovations in CSF-based diagnostics are helping clinicians better characterize disease and guide treatment decisions.

Why Education and Awareness Matter

LM remains an area of significant unmet need in oncology. For many patients, symptoms may initially be subtle or mistaken for other conditions.

Educational resources like this clinical poster aim to:

• Improve awareness of LM among patients and caregivers
• Help clinicians recognize symptoms earlier
• Support informed conversations about diagnosis and treatment options
• Highlight advances in diagnostic technologies and targeted therapies

By providing accurate, accessible information, patient advocates, clinicians, and industry collaborators can work together to improve care for people affected by this condition.

Collaboration to Support the LM Community

This educational initiative reflects a shared commitment by Leptomeningeal Cancer Foundation, CNSide Diagnostics, and Plus Therapeutics to advance awareness and support the LM community.

Through partnerships with patient advocacy organizations, these efforts help ensure that reliable information reaches those who need it most—patients, families, and healthcare professionals navigating complex cancer diagnoses.

Download the Educational Poster

Patients, caregivers, and clinicians can access the full Leptomeningeal Metastases Clinical Education Poster here:

Download the resource:
https://lnkd.in/g2wCk5JV